A free glossary of oncology-related terms and resource organizationsMore News and Special Reports
About nm|OK
Why use a resource like nm|OK?
Unlike reports that are 'dead on arrival' nm|OK is a constantly updated comprehensive report on every aspect of oncology drug development. click
Drugs profiled in nm|OK
nm|OK profiles over 4,310 drugs/in vivo imaging agents in development:
 3,653 anticancer agents addressing over 100 cancer types and thousands of clinical indications. Of these, 1,695 are in active development; 821 have been or are currently being evaluated in clinical trials and 539 of these are targeted agents.
757 drugs for the management of complications of cancer and its treatment (pain, infection, mucositis, emesis, etc.)
nm|OK also profiles over 552 marketed drugs (anticancer agents=335, adjuncts=197) globally, providing trial results from monotherapy and combination therapy trials.
In vitro testing (IVT) products
nm|OK profiles over 200 companies and hundreds of products (screening tests, diagnostics, pharmacogenomics, prognostics, disease monitoring tests, theragnostics, etc.) in the in vitro testing area in oncology.
Enabling technologies/drug delivery
nm|OK describes hundreds of technology platforms used to discover, evaluate, optimize, and or deliver anticancer agents such as cytotoxics, synthetic nucleic acid sequences, small molecule drugs, monoclonal antibodies, fusion proteins, etc.
Targets in oncology
nm|OK describes over 1,000 molecular moieties that may be target candidates of anticancer strategies or used as in vitro testing markers.
Shorthanded? Need a cost-effective way to monitor developments in oncology. New Medicine provides numerous services:
Need an update on certain items in nm|OK? click
Need to access certain records/saved searches on a routine basis? click
Require more in-depth reports on certain developments in oncology? click
Would your oncology effort benefit from an in-house resource like nm|OK that allows you to combine nm|OK with secure proprietary data? click
|
|
The headlines below refer to selected records among the hundreds updated in nm|OK within a 30-day period. A summary of the updated information, the complete records for each item on the list, and numerous other updated entries are available to subscribers upon logging in. Samples of records from each module are here. |
|
Special reports are reviews of current developments of oncology and related drugs by indication, mechanism, delivery technology, etc. as well as personalized medicine, including biomarkers, diagnostics, theragnostics, prognostics, pharmacogenomics, disease monitoring tests, etc. Samples of special reports are here.
|
|
 |
New Drugs
Saridegib IPI-926
(Jan-27-2012)
Talimogene laherparepvec OncoVEX GM-CSF, OncoVEXGMCSF, OncoVEXGM-CSF
(Jan-26-2012)
Pixantrone BBR 2778
(Jan-20-2012)
Ramucirumab IMC-1121b, IMC 1121B, LY3009806
(Jan-19-2012)
LOR-253, ML-220
(Jan-15-2012)
L-DOS47
(Jan-15-2012)
VGX-100
(Jan-10-2012)
Inhibitors of mutated enhancer of zeste homolog 2 (EZH2)
(Jan-10-2012)
Blinatumomab MT103, MT-103, MEDI-538
(Jan-10-2012)
Entinostat MS-275, MS275, SNDX-275, NSC 706995
(Jan-9-2012)
E75
(Jan-5-2012)
CBP501
(Jan-5-2012)
Tivozanib AV-951, formerly KRN951
(Jan-3-2012)
Navitoclax ABT-263, RG7423
(Dec-30-2011)
Login for details. . .
Marketed Drugs
Xgeva (cancer), Prolia (osteoporosis)
(Jan-26-2012)
Zevalin
(Jan-25-2012)
Folotyn
(Jan-20-2012)
Xalkori
(Jan-18-2012)
Adcetris
(Jan-14-2012)
Halaven
(Jan-3-2012)
Totect (USA), Savene (Europe)
(Dec-31-2011)
Dacogen
(Dec-30-2011)
Login for details. . .
|
Company
Amgen
(Jan-26-2012)
Avila Therapeutics
(Jan-26-2012)
Micromet
(Jan-26-2012)
Cleveland BioLabs
(Jan-25-2012)
EntreMed
(Jan-23-2012)
Guided Therapeutics
(Jan-23-2012)
Constellation Pharmaceuticals
(Jan-20-2012)
Clavis Pharma
(Jan-18-2012)
Ventana Medical Systems
(Jan-18-2012)
Astex Pharmaceuticals
(Jan-16-2012)
Synta Pharmaceuticals
(Jan-16-2012)
Cell Signaling Technology
(Jan-10-2012)
Forma Therapeutics
(Jan-10-2012)
QIAGEN
(Jan-10-2012)
Health Discovery
(Jan-9-2012)
NeoGenomics
(Jan-9-2012)
Apricus Biosciences
(Dec-31-2011)
Login for details. . .
Targets in Oncology
Myeloid cell leukemia sequence 1 (MCL1)
(Jan-25-2012)
Enhancer of zeste homolog 2 (EZH2)
(Jan-15-2012)
Login for details. . .
|
User Fee Programs for Generic Drugs and Biosimilars
In January 2012, the FDA completed its recommendations for 3 user fee programs including the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), and new user fee programs for human generic drugs and biosimilar biological products. (more. . .)
Avastin in Ovarian Cancer
In December 2011, the European Commission approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a first line treatment following surgery for women with advanced (Stage IIIb/c and Stage IV) epithelial ovarian, primary peritoneal or fallopian tube cancer. (more. . .)
Reprogramming Cancer Cells to Proliferate Indefinitely In Vitro
Investigators at the Lombardi Comprehensive Cancer Center, Georgetown University Medical School (Washington, DC) and the National Institutes of Health (NIH), report that Rho kinase inhibitor Y-27632, in combination with fibroblast feeder cells, induces normal cells and tumor epithelial cells from many tissues of patients with cancer to survive and proliferate indefinitely in vitro, without transduction of exogenous viral or cellular genes (Liu X, etal, Am J Pathol, 16 Dec 2011; epub ahead of print). (more. . .)
Combination of HEr2 Inhibitors in Breast Cancer
In the multicenter international, double blind, randomized phase III clinical trial (TOC4129g; WO20698; NCT00567190), known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab), that randomly assigned 808 patients with metastatic HEr2-positive breast cancer to trastuzumab and docetaxel as first line chemotherapy in combination with pertuzumab or placebo, median PFS was extended an additional 6 months (18.5 months versus 12.4 months), a 38% reduction in risk for progression without any significant increase in AE (Baselga J, etal, SABCS11, Abs. S5-5 and Baselga J, et al., NEJM, 7 Dec 2011; epub ahead of print). (more. . .)
Inhibition of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer
The success of Avastin, an antiangiogenesis agent targeting the VEGF pathway, has prompted the development of numerous similarly acting agents. Avastin, with global revenues of $6,210.5 million in fiscal 2010, is the most commercially successful anticancer drug ever to reach the market. Future Oncology has published a review of VEGF inhibition in the treatment of cancer. (more...)
Subscribers to New Medicine's Oncology KnowledgeBASE (nm|OK), log in to access the version providing active links to nm|OK records.
|
|